Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?
*Bertrand Tombal Cliniques universitaires Saint-Luc, Brussels, Belgium *Correspondance to email@example.com Disclosure: Paid investigator or advisor for Amgen, Astellas, Ferring, Bayer, Medivation, Janssen, and Sanofi-Aventis. Support: The author would like to thank Dr Caroline Charles for medical writing assistance with this manuscript. Received: 13.10.14 Accepted: 27.10.14 Citation: EMJ Oncol. 2014;2:40-47. AbstractRead More